Antenatally administered PPAR-γ agonist rosiglitazone prevents hyperoxia-induced neonatal rat lung injury
- 1 November 2010
- journal article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 299 (5) , L672-L680
Abstract
The physiological development and homeostasis of the lung alveolus is determined by the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) by the interstitial lipofibroblast. We have recently shown (Dasgupta C et al., Am J Physiol Lung Cell Mol Physiol 296: L1031–L1041, 2009.) that PPAR-γ agonists administered postnatally accelerate lung maturation and prevent hyperoxia-induced lung injury. However, whether the same occurs antenatally is not known. The objective of this study was to test the hypothesis that the potent PPAR-γ agonist rosiglitazone (RGZ), administered antenatally, enhances fetal lung maturation and protects against hyperoxia-induced neonatal lung injury. Sprague-Dawley rat dams were administered either diluent or RGZ (3 mg/kg), at late gestation, to determine its effect on lung maturation and on hyperoxia (95% O2exposure for 24 h)-induced neonatal lung injury. The lungs were examined for the expression of specific markers of alveolar development (surfactant proteins A and B, cholinephosphate cytidylyltransferase-α, leptin receptor, triglyceride uptake, and [3H]choline incorporation into saturated phosphatidylcholine) and injury/repair, in particular, the markers of transforming growth factor-β signaling (activin receptor-like kinase-5, SMAD3, lymphoid enhancer factor-1, fibronectin, and calponin). Overall, antenatal RGZ accelerated lung maturation and blocked the inhibition of alveolar sacculation and septal wall thinning by hyperoxia. RGZ specifically stimulated the development of the alveolar epithelial type II cell, the lipofibroblast, and the vasculature. The increased expression of the transforming growth factor-β intermediates, such as SMAD3 and lymphoid enhancer factor-1, implicated in hyperoxic lung injury, was also blocked by antenatal RGZ treatment. In conclusion, PPAR-γ agonists can enhance fetal lung maturation and can effectively prevent hyperoxia-induced neonatal lung injury.Keywords
This publication has 38 references indexed in Scilit:
- 1α,25(OH)2D3and its 3-epimer promote rat lung alveolar epithelial-mesenchymal interactions and inhibit lipofibroblast apoptosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- The Effects of Smoking on the Developing Lung: Insights from a Biologic Model for Lung Development, Homeostasis, and RepairLung, 2009
- Effect of maternal food restriction on fetal rat lung lipid differentiation programPediatric Pulmonology, 2009
- Lung evolution as a cipher for physiologyPhysiological Genomics, 2009
- Hyperoxia-induced neonatal rat lung injury involves activation of TGF-β and Wnt signaling and is protected by rosiglitazoneAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Peroxisome Proliferator-Activated Receptor γ Agonists Enhance Lung Maturation in a Neonatal Rat ModelPediatric Research, 2009
- A paradoxical temporal response of the PTHrP/PPARγ signaling pathway to lipopolysaccharide in an in vitro model of the developing rat lungAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Placental transfer of rosiglitazone in the ex vivo human perfusion modelAmerican Journal of Obstetrics and Gynecology, 2006
- Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, prevents hyperoxia-induced neonatal rat lung injury in vivoPediatric Pulmonology, 2006
- Metabolism and fate of neutral lipids of fetal lung fibroblast originBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995